Weight-Loss Drugs Weigh on America’s Food Basket

Estimated reading time: 3 minutes

Gone Appétit

Novo Nordisk’s (NVO) weight management medications Ozempic and Wegovy — intended for people struggling with type 2 diabetes and obesity, respectively — have shot to popularity, not least, because celebrities are open about using them.

But these weight-loss drugs might not only reduce waistlines; they could reduce bottom lines, too.

As demand for Ozempic and Wegovy surges, the food and retail industries are on high alert, concerned that the appetite suppressants may put pressure on fast-food menus and snack aisles.

Retail Rumble

Walmart (WMT) added fuel to the fire when its U.S. CEO John Furner said the retail giant was seeing the effects of people taking weight-loss drugs reflected in food shopping. The company noticed the trend by juxtaposing its pharmacy data with grocery trends: fewer units of food, fewer calories.
And this may just be beginning. Analysts at Morgan Stanley (MS) project as many as 24 million Americans —  7% of the U.S. population — will use weight-loss drugs by 2035.

Feasting Forecasts

For investors and industry stalwarts the rise of weight management drugs is a curveball that could reshape the food and retail landscape as high-calorie food products lose appeal.

However, Walmart also noted that overall sales from shoppers on the weight-loss drugs were actually higher. So while food spending might see a dip, it could be a boon to retailers in other sectors.

Disclaimer
SoFi Securities (Hong Kong) Limited and its affiliates (SoFi HK) may post or share information and materials from time to time. They should not be regarded as an offer, solicitation, invitation, investment advice, recommendation to buy, sell or otherwise deal with any investment instrument or product in any jurisdictions. Keep in mind that investing involves risk, and past performance of an asset never guarantees future results or returns. It’s important for investors to consider their specific financial needs, goals, and risk profile before making an investment decision.
SoFi HK does not make any warranties about the completeness, reliability and accuracy of this information and will not be liable for any losses and/or damages in connection with the use of this information.
The information and materials may contain hyperlinks to other websites, we are not responsible for the content of any linked sites. The information and analysis provided through hyperlinks to third party websites, while believed to be accurate, cannot be guaranteed by SoFi HK. These links are provided for informational purposes and should not be viewed as an endorsement. The risk involved in using such hyperlinks shall be borne by the visitor and subject to any Terms of Use applicable to such access and use.
Any product, logos, brands, and other trademarks or images featured are the property of their respective trademark holders. These trademark holders are not affiliated with SoFi HK or its Affiliates. These trademark holders do not sponsor or endorse SoFi HK or any of its articles.
Without prior written approval of SoFi HK, the information/materials shall not be amended, duplicated, photocopied, transmitted, circulated, distributed or published in any manner, or be used for commercial or public purposes.